Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Walenga

Showing results (121-130 of 196) with videos related to

Pageof 20
Sort By:
Seminars in Thrombosis and Hemostasis|April 1, 1985
Usefulness of fibrinopeptide A generation tests in experimental and clinical studies with low molecular weight heparin fractionsR M Emanuele, J Fareed, J M Walenga, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1982
Laboratory evaluation of antithrombin III: a critical overview of currently available methods for antithrombin III measurementsJ Fareed, H L Messmore, J M Walenga, et al.
Thrombosis Research|April 1, 1993
Evaluation of a low molecular weight heparin as an anticoagulant in a model of cardiopulmonary bypass surgeryM J Koza, H L Messmore, M E Wallock, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1991
Pharmacological and clinical studies with Lomoparan, a low molecular weight glycosaminoglycanM T Nurmohamed, J Fareed, D Hoppensteadt, et al.
Thrombosis Research|October 29, 2000
Human anti-heparin-platelet factor 4 antibodies are capable of activating primate platelets: towards the development of a HIT model in primatesS Ahmad, W P Jeske, J M Walenga, et al.
Archives of Pathology & Laboratory Medicine|November 18, 2000
Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications--a reviewF Fabris, S Ahmad, G Cella, et al.
Journal of the American College of Surgeons|April 1, 1994
Interleukin-2 and interleukin-6 in relation to burn wound size in the acute phase of thermal injuryA Kowal-Vern, J M Walenga, D Hoppensteadt, et al.
British Journal of Haematology|June 10, 2000
Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activationJ Amiral, C Pouplard, A M Vissac, et al.
Haemostasis|January 1, 1988
Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparinsJ Fareed, J M Walenga, A Racanelli, et al.
Thrombosis Research|August 15, 1989
Comparative pharmacology of low molecular weight heparins: implications of manufacturing processes on biological effectsC Doutremepuich, M Guyot, M C Lalanne, et al.
Pageof 20

Showing results (121-130 of 196) with videos related to

Sort By:
Pageof 20
Seminars in Thrombosis and Hemostasis|April 1, 1985
Usefulness of fibrinopeptide A generation tests in experimental and clinical studies with low molecular weight heparin fractionsR M Emanuele, J Fareed, J M Walenga, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1982
Laboratory evaluation of antithrombin III: a critical overview of currently available methods for antithrombin III measurementsJ Fareed, H L Messmore, J M Walenga, et al.
Thrombosis Research|April 1, 1993
Evaluation of a low molecular weight heparin as an anticoagulant in a model of cardiopulmonary bypass surgeryM J Koza, H L Messmore, M E Wallock, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1991
Pharmacological and clinical studies with Lomoparan, a low molecular weight glycosaminoglycanM T Nurmohamed, J Fareed, D Hoppensteadt, et al.
Thrombosis Research|October 29, 2000
Human anti-heparin-platelet factor 4 antibodies are capable of activating primate platelets: towards the development of a HIT model in primatesS Ahmad, W P Jeske, J M Walenga, et al.
Archives of Pathology & Laboratory Medicine|November 18, 2000
Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications--a reviewF Fabris, S Ahmad, G Cella, et al.
Journal of the American College of Surgeons|April 1, 1994
Interleukin-2 and interleukin-6 in relation to burn wound size in the acute phase of thermal injuryA Kowal-Vern, J M Walenga, D Hoppensteadt, et al.
British Journal of Haematology|June 10, 2000
Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activationJ Amiral, C Pouplard, A M Vissac, et al.
Haemostasis|January 1, 1988
Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparinsJ Fareed, J M Walenga, A Racanelli, et al.
Thrombosis Research|August 15, 1989
Comparative pharmacology of low molecular weight heparins: implications of manufacturing processes on biological effectsC Doutremepuich, M Guyot, M C Lalanne, et al.
Pageof 20